Header

UZH-Logo

Maintenance Infos

Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked


Huber, M; von Wyl, V; Ammann, C G; Kuster, H; Stiegler, G; Katinger, H; Weber, R; Fischer, M; Stoiber, H; Günthard, H F; Trkola, A (2008). Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked. Journal of Virology, 82(8):3834-3842.

Abstract

To evaluate the contribution of complement-mediated lysis to the in vivo activities of neutralizing antibodies, we analyzed the influence of complement activation on treatment success in a recent passive immunization trial with the neutralizing monoclonal antibodies 2G12, 2F5, and 4E10. Administration of monoclonal antibodies led to an immediate, high activation of the complement system even in the absence of viremia in the 14 participating human immunodeficiency virus-infected individuals. Lysis activity measured in patient plasma increased during passive immunization; however, the increases were modest and only partially attributable to the administration of antibodies. We found that unlike neutralization activity, lysis activity was not associated with treatment success in this trial. Compared to complement lysis mounted by the polyclonal antibody response in vivo, monoclonal antibodies were weak inducers of this activity, suggesting that polyclonal responses are more effective in reaching the required threshold of complement activation. Importantly, strong neutralization activity of the monoclonal antibodies did not predict complement lysis activity against patient and reference viruses, suggesting that these activities are not linked. In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity.

Abstract

To evaluate the contribution of complement-mediated lysis to the in vivo activities of neutralizing antibodies, we analyzed the influence of complement activation on treatment success in a recent passive immunization trial with the neutralizing monoclonal antibodies 2G12, 2F5, and 4E10. Administration of monoclonal antibodies led to an immediate, high activation of the complement system even in the absence of viremia in the 14 participating human immunodeficiency virus-infected individuals. Lysis activity measured in patient plasma increased during passive immunization; however, the increases were modest and only partially attributable to the administration of antibodies. We found that unlike neutralization activity, lysis activity was not associated with treatment success in this trial. Compared to complement lysis mounted by the polyclonal antibody response in vivo, monoclonal antibodies were weak inducers of this activity, suggesting that polyclonal responses are more effective in reaching the required threshold of complement activation. Importantly, strong neutralization activity of the monoclonal antibodies did not predict complement lysis activity against patient and reference viruses, suggesting that these activities are not linked. In summary, our data support the notion that the in vivo activities of 2G12, 2F5, and 4E10 are likely due to direct neutralization or Fc receptor-mediated mechanisms such as phagocytosis and antibody-dependent cellular cytotoxicity.

Statistics

Citations

Dimensions.ai Metrics
17 citations in Web of Science®
20 citations in Scopus®
23 citations in Microsoft Academic
Google Scholar™

Altmetrics

Downloads

105 downloads since deposited on 17 Nov 2008
11 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Infectious Diseases
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:2008
Deposited On:17 Nov 2008 16:00
Last Modified:18 Feb 2018 09:47
Publisher:American Society for Microbiology
ISSN:0022-538X
Additional Information:Copyright: American Society for Microbiology
OA Status:Hybrid
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1128/JVI.02569-07
PubMed ID:18234794

Download

Download PDF  'Potent human immunodeficiency virus-neutralizing and complement lysis activities of antibodies are not obligatorily linked'.
Preview
Filetype: PDF
Size: 1MB
View at publisher